High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40kd) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin

被引：20
|
作者：
Nelson, D. [1 ]
Pockros, P. J. [2 ]
Godofsky, E. [3 ]
Rodriguez-Torres, M. [4 ]
Everson, G. [5 ]
Fried, M. [6 ]
Ghalib, R. [7 ]
Harrison, S. [8 ]
Nyberg, L. [9 ]
Shiffman, M. [10 ]
Chan, A.
Hill, G.
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Scripps Clin, La Jolla, CA 92037 USA
[3] Univ Hepatitis Ctr Bach & Godofsky, Bradenton, FL USA
[4] Fdn Invest Diego, Santurce, PR USA
[5] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[6] Univ N Carolina, Chapel Hill, NC USA
[7] Dallas Methodist Hosp, Liver Inst, Dallas, TX USA
[8] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA
[9] Kaiser Permanente, San Diego, CA USA
[10] Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23284 USA
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
10.1016/S0168-8278(08)60995-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
993
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [1] Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV
    Andriulli, Angelo
    Mangia, Alessandra
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (16): : 1660 - 1660
  • [2] Prospective evaluation of peginterferon alfa-2a (40KD)/ribavirin in CHC, IFN/ribavirin nonresponders/relapsers
    Parise, E
    Meirelles, A
    Martinelli, A
    Lacet, C
    Correa, E
    Cotrim, H
    Settee, H
    Cheinquer, H
    Gallizi, J
    Fonseca, J
    Parana, R
    da Silva, R
    Spinelli, V
    Gomes, A
    Crespo, D
    Lima, L
    Pereira, L
    Tiexeira, R
    Amorim, W
    Tatsch, F
    JOURNAL OF HEPATOLOGY, 2003, 38 : 161 - 161
  • [3] A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin
    Ferenci, Peter
    Aires, Rodrigo
    Ancuta, Ioan
    Arohnson, Andrew
    Cheinquer, Hugo
    Delic, Dragan
    Gschwantler, Michael
    Larrey, Dominique
    Tallarico, Ludovico
    Schmitz, Manuela
    Tatsch, Fernando
    Ouzan, Denis
    LIVER INTERNATIONAL, 2014, 34 (10) : 1550 - 1559
  • [4] Treatment duration and histological response to peginterferon alfa-2a/ribavirin
    Pockros, Paul
    Martin, Paul
    Hamzeh, Fayez M.
    Lentz, Ellen
    Lok, Anna
    GASTROENTEROLOGY, 2007, 132 (04) : A790 - A790
  • [5] Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial.
    Bronowicki, JP
    Ouzan, D
    Tzanck, A
    Asselah, T
    Desmorat, H
    Zarski, JP
    Foucher, J
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Chevallier, M
    Bouvier, M
    Lonjon-Domanec, I
    Pawlotsky, JM
    HEPATOLOGY, 2003, 38 (04) : 244A - 245A
  • [6] Combination of Levovirin (LVV) and peginterferon alfa-2a (40 KD) (Pegasys®) fails to generate a virological response comparable to ribavirin (RBV, Copegus®) and peginterferon alfa-2a (40KD) in patients with chronic hepatitis
    Pockros, PJ
    Pessoa, MG
    Diago, M
    Martinelli, ADC
    Berg, T
    Germanidis, G
    Lai, MY
    Gomez, HR
    Goeser, T
    Roberts, S
    Sheen, IS
    Hsien, T
    Hinrichsen, HM
    Lee, SS
    Reindollar, R
    Sola, R
    Wilson, K
    Jorga, K
    Graham, P
    Jackson, H
    HEPATOLOGY, 2004, 40 (04) : 391A - 391A
  • [7] Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
    Shiffman, Mitchell L.
    Suter, Fredy
    Bacon, Bruce R.
    Nelson, David
    Harley, Hugh
    Sola, Ricard
    Shafran, Stephen D.
    Barange, Karl
    Lin, Amy
    Soman, Ash
    Zeuzem, Stefan
    Crawford, D.
    Leggett, L.
    Roberts, S.
    Weltman, M.
    Greenbloom, S.
    Menon, K.
    Bourliere, M.
    Brissot, P.
    Bronowicki, J.-P.
    Doffoel, M.
    Hezode, C.
    Marcellin, P.
    Tran, A.
    Zarski, J.-P.
    Avci, O.
    Berg, T.
    Potthoff, O.
    Rasenack, J.
    Ross, O.
    von Wagner, M.
    Ascione, A.
    Brillanti, S.
    Brunetto, M.
    Bruno, R.
    Bruno, S.
    Cane, E.
    Aguilar, J.
    Barcena, R.
    Diago, M.
    Enriquez, J.
    Garcia-Samaniego, J.
    Moreno, R.
    Planas, R.
    Rincon, D.
    Sola, R.
    Testillano, M.
    Anand, B.
    Bilir, B. Bahri
    Balan, V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (02): : 124 - 134
  • [8] Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) and ribavirin in patients with or without drug use
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Bernd
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A840 - A840
  • [9] Predictive factors in treatment of chronic hepatitis c (cHC) patients with peginterferon alfa-2a (40KD) and ribavirin
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Berrid
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A839 - A839
  • [10] HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN HCV GENOTYPE 1 RELAPSER PATIENTS RETREATED WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN FOR 72 WEEKS
    Kaiser, Stephan
    Lutze, Bettina
    Hass, Holer G.
    Werner, Christoph R.
    HEPATOLOGY, 2008, 48 (04) : 1140A - 1140A
12345